David Risinger
Stock Analyst at Leerink Partners
(3.58)
# 863
Out of 5,117 analysts
174
Total ratings
65.96%
Success rate
14.55%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $22.23 | +43.95% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $26.06 | +72.68% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,077.75 | +2.44% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $5.80 | +417.24% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $68.87 | +1.64% | 4 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $458 → $456 | $462.90 | -1.49% | 5 | Sep 25, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $207.63 | -26.31% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $784.97 | +6.25% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $229.98 | -10.43% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $54.64 | +33.60% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $20.88 | +230.46% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $12.67 | +26.28% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $31.70 | +38.80% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $46.97 | +225.74% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $18.84 | -46.92% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $50.10 | -6.19% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $332.93 | -4.48% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $25.33 | -56.57% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $124.70 | -27.02% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $25.09 | +91.31% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $7.18 | +415.32% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $170.48 | +3.24% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $12.32 | +29.87% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $13.82 | +225.62% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $7.20 | +386.11% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $22.60 | +81.42% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $126.23 | +37.84% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $39.22 | +30.04% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $31.89 | -74.91% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $106.78 | -16.65% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.95 | -76.83% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $28.49 | -43.84% | 9 | Apr 2, 2020 |
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $22.23
Upside: +43.95%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $26.06
Upside: +72.68%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,077.75
Upside: +2.44%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $5.80
Upside: +417.24%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $68.87
Upside: +1.64%
Vertex Pharmaceuticals
Sep 25, 2025
Upgrades: Outperform
Price Target: $458 → $456
Current: $462.90
Upside: -1.49%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $207.63
Upside: -26.31%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $784.97
Upside: +6.25%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $229.98
Upside: -10.43%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $54.64
Upside: +33.60%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $20.88
Upside: +230.46%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $12.67
Upside: +26.28%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $31.70
Upside: +38.80%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $46.97
Upside: +225.74%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $18.84
Upside: -46.92%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $50.10
Upside: -6.19%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $332.93
Upside: -4.48%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $25.33
Upside: -56.57%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $124.70
Upside: -27.02%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.09
Upside: +91.31%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $7.18
Upside: +415.32%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $170.48
Upside: +3.24%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $12.32
Upside: +29.87%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $13.82
Upside: +225.62%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $7.20
Upside: +386.11%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $22.60
Upside: +81.42%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $126.23
Upside: +37.84%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $39.22
Upside: +30.04%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $31.89
Upside: -74.91%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $106.78
Upside: -16.65%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.95
Upside: -76.83%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $28.49
Upside: -43.84%